Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Sponsor
Astellas Pharma Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT00189774
Collaborator
Ajinomoto USA, INC. (Industry)
7
Study Details
Study Description
Brief Summary
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2/Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Type 2 diabetes mellitus under the treatment with pioglitazone
Exclusion Criteria:
-
Patients who cannot follow the diet therapy and/or exercise therapy
-
Type 1 diabetes mellitus
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chubu region | Japan | |||
| 2 | Chugoku region | Japan | |||
| 3 | Hokkaido region | Japan | |||
| 4 | Kanto region | Japan | |||
| 5 | Kinki region | Japan | |||
| 6 | Kyushu region | Japan | |||
| 7 | Tohoku region | Japan |
Sponsors and Collaborators
- Astellas Pharma Inc
- Ajinomoto USA, INC.
Investigators
- Study Director: Study Director, Astellas Pharma Inc
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00189774
Other Study ID Numbers:
- 026-CL-004
First Posted:
Sep 19, 2005
Last Update Posted:
Mar 13, 2008
Last Verified:
Mar 1, 2008
Keywords provided by ,
,
Additional relevant MeSH terms: